Moving to All Oral Therapy for Hepatitis C

Two more studies show the promise of all oral treatment for Hepatitis C virus:

  • NEJM 2014; 370: 211-21.
  • NEJM 2014; 370: 222-32.

A summary of these articles is available at the following link: http://t.co/Z8jMPKoLGz.

Here is an excerpt:

Hepatitis C treatment isn’t pretty, but the dark days of weekly injections, rough side effects and no guarantee of full recovery from the liver-damaging disease may soon be over, researchers report.

Two studies, both published in the Jan. 16 issue of the New England Journal of Medicine, involved giving various combinations of antiviral pill cocktails to patients with hepatitis C. Some had failed to respond to standard treatments, and some had not received treatment yet. Yet, the cocktails cleared the virus in both studies for between 93 percent and 98 percent of the patients…

The first study, conducted by Johns Hopkins researchers, included 211 men and women with hepatitis C who took two pill-form antiviral medications, daclatasvir and sofosbuvir. The patients were treated at 18 medical centers in the United States and Puerto Rico. They took 60 milligrams of daclatasvir and 400 milligrams of sofosbuvir for either 12 or 24 weeks, with or without a third drug, ribavirin….

98 percent of the 126 previously untreated patients and 98 percent of 41 patients whose infections had not cleared despite treatment with standard hepatitis C therapy, were considered cured. “There was no detectable virus in their blood three months after the treatment stopped,” he noted.

The second study, headed up by researchers at Virginia Mason Medical Center in Seattle, involved more than eight medical centers in the United States and internationally. It included 571 patients with hepatitis C, some of whom had not received treatment previously and others who had previously received standard treatments with interferon injections and ribavirin — an antiviral drug that when given reduces relapses — but had not responded to them.

The participants were randomly assigned to take any of three combinations of antiviral pills — medications called ABT-450, ABT-267, and ABT-333 — for eight, 12 or 24 weeks…

Almost all of the patients (more than 93 percent in both groups) saw the virus cleared from their systems within 24 weeks.

Bottomline: Once daily treatment with a combination of medicines will be an effective and safe cure for more than 90% of individuals with HCV. Whether these agents will be affordable remains in doubt.

Related blog posts: